New Triple-Drug attack on breast cancer shows promise in Late-Stage trial
Disease control
Recruiting now
This phase 3 trial is testing whether adding a new oral drug called JS105 to two standard drugs (dalpiciclib and fulvestrant) can better control advanced breast cancer in people with a PIK3CA gene mutation. The study will enroll 312 adults with HR-positive, HER2-negative breast c…
Phase: PHASE3 • Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC